Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Body Composition and Inflammatory-Metabolic Indices as Prognostic Markers in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI Study

NCT07192926 is registered in ClinicalTrials.gov with Ankara Etlik City Hospital as lead sponsor.

NCT NCT07192926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07192926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Body Composition and Inflammatory-Metabolic Indices as Prognostic Markers in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI Study
Lead sponsor
Ankara Etlik City Hospital
Phase
Observational
Overall status
Completed
Start date
December 1, 2022
Completion date
June 11, 2026
Enrollment
155 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-small cell lung cancer, neoplasm